Epitalon and IllumiNeuro Protocol Interaction: Compatible | Peptide Database

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.

Join others researching Oxandrolone — share findings, ask questions, and learn from real experiences Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings. Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.